Patents by Inventor David Jonathan Glass

David Jonathan Glass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210172020
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Application
    Filed: August 6, 2020
    Publication date: June 10, 2021
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael C. Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20210002377
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: May 27, 2020
    Publication date: January 7, 2021
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Publication number: 20200392159
    Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 17, 2020
    Inventors: Simone BONAZZI, Michael CONNOLLY, David Jonathan GLASS, Manuel MIHALIC, Andrew William PATTERSON, Silvio ROGGO, Tea SHAVLAKADZE
  • Publication number: 20200339651
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
    Type: Application
    Filed: December 9, 2019
    Publication date: October 29, 2020
    Inventors: Jennifer Brogdon, Gregory Beatty, David Jonathan Glass, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Huijuan Song, Qilong Wu
  • Patent number: 10800793
    Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: October 13, 2020
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Michael Connolly, David Jonathan Glass, Manuel Mihalic, Andrew William Patterson, Silvio Roggo, Tea Shavlakadze
  • Patent number: 10774388
    Abstract: Cancer biomarkers and methods of using them are disclosed.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: September 15, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Felipe Bedoya, Hans Bitter, Jennifer Brogdon, Corin Dorfmeier, Abhishek Garg, David Jonathan Glass, Joan Mannick, Jan J. Melenhorst, Michael Milone, Leon Murphy, Elena Orlando, Nicholas Wilcox
  • Publication number: 20200215171
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 9, 2020
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Jonathan Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Patent number: 10703819
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 7, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Publication number: 20190388471
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 26, 2019
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph A. Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Jonathan Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Publication number: 20190263914
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Application
    Filed: December 5, 2018
    Publication date: August 29, 2019
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • Publication number: 20190153061
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 23, 2019
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • Patent number: 10287354
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 14, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • Publication number: 20190092788
    Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.
    Type: Application
    Filed: September 25, 2018
    Publication date: March 28, 2019
    Inventors: Simone BONAZZI, Michael CONNOLLY, David Jonathan GLASS, Manuel MIHALIC, Andrew William PATTERSON, Silvio ROGGO, Tea SHAVLAKADZE
  • Publication number: 20180312595
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: October 6, 2017
    Publication date: November 1, 2018
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Patent number: 10030063
    Abstract: The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as IGF-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a. Cultivating said cell under conditions allowing the expression of the therapeutic protein; and b. Harvesting the therapeutic protein from the mammalian cell cultivated in step a, wherein said mammalian cell produces at least 1.5 fold more therapeutic protein than a cell in which the expression of the cognate receptor has not been so modified.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: July 24, 2018
    Assignee: Novartis AG
    Inventors: Mara Fornaro, David Jonathan Glass, Thomas Jostock, Holger Laux, Sandrine Romand
  • Publication number: 20170066808
    Abstract: The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.
    Type: Application
    Filed: January 15, 2014
    Publication date: March 9, 2017
    Applicant: NOVARTIS AG
    Inventors: David Jonathan GLASS, Mara FORNARO
  • Publication number: 20160311907
    Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 27, 2016
    Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
  • Publication number: 20160271265
    Abstract: This relates to the use of an IGF-1 mimetic in human therapy. In particular, disclosed herein is the use of an IGF-1 precursor protein, particularly a human IGF-1 precursor protein, comprising the E-peptide for the treatment of Spinal and Bulbar Muscular Atrophy (SBMA) in a patient suffering from said disease.
    Type: Application
    Filed: September 30, 2014
    Publication date: September 22, 2016
    Applicants: NOVARTIS AG, NATIONAL INSTITUTES OF HEALTH
    Inventors: Kenneth FISCHBECK, David Jonathan GLASS
  • Publication number: 20150322131
    Abstract: The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as IGF-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a. Cultivating said cell under conditions allowing the expression of the therapeutic protein; and b. Harvesting the therapeutic protein from the mammalian cell cultivated in step a, wherein said mammalian cell produces at least 1.5 fold more therapeutic protein than a cell in which the expression of the cognate receptor has not been so modified.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Mara FORNARO, David Jonathan GLASS, Thomas JOSTOCK, Holger LAUX, Sandrine ROMAND
  • Publication number: 20140235538
    Abstract: The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented.
    Type: Application
    Filed: January 15, 2014
    Publication date: August 21, 2014
    Applicant: NOVARTIS AG
    Inventors: David Jonathan GLASS, Mara FORNARO